Minden C. Collamore, DO

COPC Polaris

Provider Overview

Accepting New Patients

Yes – Age 14 and up

Specialty

Family Medicine

Languages Spoken

English

Provider Background

About Minden C. Collamore, DO

I enjoy spending time with my dog Lilo. I like to paint in my spare time and enjoy watching NWSL soccer games. I also enjoy going to the gym to lift weights.

Areas of Interest

  • Integrative Medicine

  • Diabetes Management

  • Osteopathic Manipulative Medicine

  • Women's Health

Hospital Admitting Privileges

St. Ann’s, Riverside

Residency

Mount Carmel, St. Anns

Associations & Organizations

AAFP , AOA

Publications

Lam, E.T., Ringel, M.D., Kloos, R.T., Prior, T.W., Knopp, M.D, Jiachao, L., Sammet, S., Hall, N.C, Wakely, P.E., Vasko, V.V., Saji, M., Snyder, P.J., Wei, L., Arbogast, D., Collamore, M.Wright, J.J., Moley, J.F., Villalona-Calero, M.A., Shah, M.H. (2010) Phase II Trial of Sorafenib in Mestatic Medullary Thyroid Cancer. Clinical Oncolog(14): 2323-30.


Shah, M.H., Varker, K.A., Collamore, M.Zwiebel, J.A., Coit, D., Kelsen, D., Chung, K.Y. (2009) G3 l 39 (Genasesne) in Patients with Advanced Merkel Cell Carcinoma. Am Clinical Oncology 32(2): 174-9.


Kloos, R.T., Ringel, M.D., Knopp, M.V., Hall, N.C., King, M., Stevens, R., Liang, J., Wakely, P.E., Vasko, V.V., Saji, M., Rittenberry, J., Wei, L., Arbogast, D., Collamore, M.Wright, J.J., Grever, M., Shah, M.H. (2009) Phase II Trial of Sorafenib in Metastatic Thyroid Cancer. Clinical Oncology 27( I 0): 1675-84.

Woyach, J. A., Kloos, R.T., Ringel, M.D., Arbogast, D., Collamore, M., Zwiebel, J.A., Grever, M., Villalona-Calero, M., Shah, M.H. (2009) Lack of Therapeutic Effect of the Histone Deacetyase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma. Clin Endocrinology and Metabolism 94(1 ): 164-70.


Shah, M.H., Binkley, P., Chan, K., Xiao, J., Arbogast, D., Collamore, M.Farra, Y., Young, D., Grever, M. (2006) Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors. Clinical Cancer Research 12(13): 3997-4003.


Butcher, G.Q., Doner, J., Dziema, H., CollamoreM.Burgoon, P.W., Obrietan, K(2002) The p42/44 Mitogen-Activated Protein Kinase Pathway Couples Photic Input to Circadian Clock Entrainment. BiologicaChemistry 277(33): 29519-25.

Medical School

Ohio University Heritage College of Osteopathic Medicine

Board Certification

Family Medicine

Insurances Accepted

  • Aetna
  • Aetna Medicare (COPC Senior Care Advantage Participant)
  • Anthem Blue Cross Blue Shield
  • Anthem Medicare (COPC Senior Care Advantage Participant)
  • Anthem Medicare (HMO & PPO Traditional)
  • Cigna
  • First Health
  • HealthSmart
  • Humana Commercial
  • Medical Mutual of Ohio (MMO)
  • Medical Mutual OhioHealth HMO
  • Medicare
  • MediGold (COPC Senior Care Advantage Participant)
  • Multiplan
  • Ohio Health Choice (OHCP)
  • OhioHealthy
  • OSU Health Plans
  • PHCS
  • PPO Connect
  • Railroad Medicare
  • Self-pay
  • UnitedHealthcare
  • UnitedHealthcare Community Plan

Patient resources

Patient Forms

Download printable patient forms before your next visit to save time.

View Forms
Telehealth Visits

Discover how to have a virtual appointment with your COPC provider.

View Details
Billing and Insurance

See the insurances we accept. Providers will vary, check their profile for details.

View Insurances
Bill Pay

View statements and securely pay your medical bills online.

Pay Bill
Patient Portal

View medical records, lab results, and more on the Patient Portal.

Visit the Portal
Contact Us

Get in touch with us for information and assistance.

Get Assistance
Central Ohio Primary Care Logo

Minden C. Collamore, DO

COPC Polaris


Gender

Female

Specialty

Family Medicine

Medical School

Ohio University Heritage College of Osteopathic Medicine

Board Certification

Family Medicine

Languages Spoken

English

Hospital Admitting Privileges

St. Ann’s, Riverside

Accepting New Patients

Yes

Residency

Mount Carmel, St. Anns

Associations & Organizations

AAFP , AOA



Publications

Lam, E.T., Ringel, M.D., Kloos, R.T., Prior, T.W., Knopp, M.D, Jiachao, L., Sammet, S., Hall, N.C, Wakely, P.E., Vasko, V.V., Saji, M., Snyder, P.J., Wei, L., Arbogast, D., Collamore, M.Wright, J.J., Moley, J.F., Villalona-Calero, M.A., Shah, M.H. (2010) Phase II Trial of Sorafenib in Mestatic Medullary Thyroid Cancer. Clinical Oncolog(14): 2323-30.


Shah, M.H., Varker, K.A., Collamore, M.Zwiebel, J.A., Coit, D., Kelsen, D., Chung, K.Y. (2009) G3 l 39 (Genasesne) in Patients with Advanced Merkel Cell Carcinoma. Am Clinical Oncology 32(2): 174-9.


Kloos, R.T., Ringel, M.D., Knopp, M.V., Hall, N.C., King, M., Stevens, R., Liang, J., Wakely, P.E., Vasko, V.V., Saji, M., Rittenberry, J., Wei, L., Arbogast, D., Collamore, M.Wright, J.J., Grever, M., Shah, M.H. (2009) Phase II Trial of Sorafenib in Metastatic Thyroid Cancer. Clinical Oncology 27( I 0): 1675-84.

Woyach, J. A., Kloos, R.T., Ringel, M.D., Arbogast, D., Collamore, M., Zwiebel, J.A., Grever, M., Villalona-Calero, M., Shah, M.H. (2009) Lack of Therapeutic Effect of the Histone Deacetyase Inhibitor Vorinostat in Patients with Metastatic Radioiodine-Refractory Thyroid Carcinoma. Clin Endocrinology and Metabolism 94(1 ): 164-70.


Shah, M.H., Binkley, P., Chan, K., Xiao, J., Arbogast, D., Collamore, M.Farra, Y., Young, D., Grever, M. (2006) Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors. Clinical Cancer Research 12(13): 3997-4003.


Butcher, G.Q., Doner, J., Dziema, H., CollamoreM.Burgoon, P.W., Obrietan, K(2002) The p42/44 Mitogen-Activated Protein Kinase Pathway Couples Photic Input to Circadian Clock Entrainment. BiologicaChemistry 277(33): 29519-25.